390. Parker AG, Byars A, Purpura M, Jäger R. The effects of alphaglycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility. J Int Soc Sports Nutr. BioMed Central; 2015;12 (Suppl 1):P41. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4595381/
391. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;CD000269. https://pubmed.ncbi.nlm.nih.gov/15846601/
392. Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016;36:1059–65. https://pubmed.ncbi.nlm.nih.gov/27587069/
393. Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, et al. The Citicholinage Study: citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 2017;56:557–65. https://pubmed.ncbi.nlm.nih.gov/28035929/
394. Cotroneo AM, Castagna A, Putignano S, Lacava R, Fantò F, Monteleone F, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131–37. https:// pubmed.ncbi.nlm.nih.gov/23403474/
395. McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23:121–34. https://pubmed.ncbi.nlm.nih.gov/26179181/
396. McGlade E, Locatelli A, Hardy J, Kamiya T, Morita M, Morishita K, et al. Improved attentional performance following citicoline administration in healthy adult women. FNS. 2012;03:769–73. https://www.scirp.org/journal/ paperinformation.aspx?paperid=19921
397. Patocka J. Huperzine A – an interesting anticholinesterase compound from the Chinese herbal medicine. Acta Medica. 1998;41:155–57. https://pubmed.ncbi.nlm.nih.gov/9951045/
398. Dos Santos TC, Gomes TM, Pinto BAS, Camara AL, Paes AM de A. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer’s disease therapy. Front Pharmacol. 2018;9:1192. https://pubmed.ncbi.nlm.nih.gov/30405413/
399. Yang G, Wang Y, Tian J, Liu J-P. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8:e74916. https://pubmed.ncbi.nlm.nih.gov/24086396/
400. Xing S-H, Zhu C–X, Zhang R, An L. Huperzine A in the treatment of Alzheimer’s disease and vascular dementia: a meta-analysis. Evid Based Complement Alternat Med. 2014;2014:363985. https://www.hindawi.com/ journals/ecam/2014/363985/
401. Zheng W, Xiang Y-Q, Ungvari GS, Chiu FKH, H Ng C, Wang Y, et al. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch Psychiatry. 2016;28:64–71. https://minerva-access.unimelb.edu.au/ handle/11343/256395
402. Hepsomali P, Groeger JA, Nishihira J, Scholey A. Effects of oral gammaaminobutyric acid (GABA) administration on stress and sleep in humans: a systematic review. Front Neurosci. 2020;14:923. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527439/
403. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3:271–80. https://pubmed.ncbi.nlm.nih.gov/9727088/
404. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;CD003198. https://pubmed.ncbi.nlm.nih.gov/11869656/
405. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutr Rev. 2020;78:77–88. https://pubmed.ncbi.nlm.nih.gov/31504850/
406. Jacobsen JPR, Krystal AD, Krishnan KRR, Caron MG. Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale. Trends Pharmacol Sci. 2016;37:933–44. https:// pubmed.ncbi.nlm.nih.gov/27692695/
407. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29:517–27. https://pubmed.ncbi.nlm.nih.gov/25384672/
408. Bukhari SI, Manzoor M, Dhar MK. A comprehensive review of the pharmacological potential of Crocus sativus and its bioactive apocarotenoids. Biomed Pharmacother. 2018;98:733–45. https://pubmed.ncbi.nlm.nih.gov/ 29306211/
409. Khaksarian M, Behzadifar M, Behzadifar M, Alipour M, Jahanpanah F, Re TS, et al. The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis. Psychol Res Behav Manag. 2019;12:297–305. https://pubmed.ncbi.nlm.nih.gov/ 31118846/
410. Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, et al. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Med. 2019;85:24–31. https://pubmed.ncbi.nlm.nih.gov/30036891/
411. Yang X, Chen X, Fu Y, Luo Q, Du L, Qiu H, et al. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2018;14:1297–305. https://pubmed.ncbi.nlm.nih.gov/29849461/
412. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11:377–83. https://pubmed.ncbi.nlm.nih.gov/24299602/
413. Khaksarian M, The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine.
Conclusion
1. Ito TA, Larsen JT, Smith NK, Cacioppo JT. Negative information weighs more heavily on the brain: the negativity bias in evaluative categorizations. J Pers Soc Psychol. 1998;75:887–900. https://pubmed.ncbi.nlm.nih.gov/9825526/
2. Smith NK, Cacioppo JT, Larsen JT, Chartrand TL. May I have your attention, please: electrocortical responses to positive and negative stimuli. Neuropsychologia. 2003;41:171–83. https://psycnet.apa.org/ record/2003-04041-010